Skip to main content

Advertisement

SpringerLink
Log in

Evaluation and Treatment of Overactive Bladder after History of Cancer Treatment

  • Overactive Bladder (U Lee, Section Editor)
  • Published:
Current Bladder Dysfunction Reports Aims and scope Submit manuscript

Abstract

Overactive bladder (OAB) syndrome is a common condition associated with a lower quality of life. It poses a significant health burden to patients and cost to the health care system. The etiology of OAB symptoms after cancer treatment may be idiopathic or neurogenic. Pelvic surgery and radiation are associated with neurogenic changes that can cause OAB symptoms. Comprehensive evaluation is indicated in this high-risk group. Management of OAB symptoms is patient centered with a focus on initiating therapy with the fewest side effects that are reversible. Behavioral, medical therapy, botulinum injections, sacral neuromodulation (SNM), percutaneous tibial nerve stimulation (PTNS), and urinary reconstruction will be discussed. An in-depth discussion about each of the treatment options will assist in selecting the optimal treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Groutz A, Blaivas JG, Chaikin DC, Weiss JP, Verhaaren M. The pathophysiology of post-radical prostatectomy incontinence: a clinical and video urodynamic study. J Urol. 2000;163(6):1767–70.

    Article  CAS  PubMed  Google Scholar 

  2. Chao R, Mayo ME. Incontinence after radical prostatectomy: detrusor or sphincter causes. J Urol. 1995;154(1):16–8.

    Article  CAS  PubMed  Google Scholar 

  3. Elliot C, Comiter C. Post-prostatectomy voiding dysfunction. Curr Bladder Dysfunct Rep. 2011;6:211–7.

    Article  Google Scholar 

  4. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358(12):1250–61.

    Article  CAS  PubMed  Google Scholar 

  5. van Tol-Geerdink JJ, Leer JW, van Oort IM, van Lin EJ, Weijerman PC, Vergunst H, et al. Quality of life after prostate cancer treatments in patients comparable at baseline. Br J Cancer. 2013;108(9):1784–9.

    Article  PubMed Central  PubMed  Google Scholar 

  6. Tekkis PP, Cornish JA, Remzi FH, Tilney HS, Strong SA, Church JM, et al. Measuring sexual and urinary outcomes in women after rectal cancer excision. Dis Colon Rectum. 2009;52(1):46–54.

    Article  CAS  PubMed  Google Scholar 

  7. Wein A, Dmochowski R. Neuromuscular dysfunction of the lower urinary tract. In: Wein, editor. Campbell-Walsh urology. 10th ed. Philadelphia: Elsevier; 2012. p. 1909–46. A comprehensive review that describes neuromuscular lower urinary tract dysfunction and its evaluation and treatment.

  8. Abrams P, Andersson KE, Birder L, Brubaker L, Cardozo L, Chapple C, et al. Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn. 2010;29(1):213–40.

    Article  CAS  PubMed  Google Scholar 

  9. Marinkovic SP, Rovner ES, Moldwin RM, Stanton SL, Gillen LM, Marinkovic CM. The management of overactive bladder syndrome. BMJ. 2012;344:e2365.

    Article  PubMed  Google Scholar 

  10. Bosch JL, Norton P, Jones JS. Should we screen for and treat lower urinary tract dysfunction after major pelvic surgery? ICI-RS 2011. Neurourol Urodyn. 2012;31(3):327–9.

    Article  PubMed  Google Scholar 

  11. Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol. 2012;188(6 Suppl):2455–63. This is a detailed review of the diagnosis and treatment guidelines for idiopathic overactive bladder. A straightforward schematic treatment algorithm provides an excellent overview.

    Article  PubMed  Google Scholar 

  12. Goode PS, Burgio KL, Locher JL, Umlauf MG, Lloyd LK, Roth DL. Urodynamic changes associated with behavioral and drug treatment of urge incontinence in older women. J Am Geriatr Soc. 2002;50(5):808–16.

    Article  PubMed  Google Scholar 

  13. Kurpad R, Kennelly MJ. The evaluation and management of refractory neurogenic overactive bladder. Curr Urol Rep. 2014;15(10):444. This is an excellent summary of the current literature on the treatment and diagnosis of neurogenic refractory overactive bladder.

    Article  PubMed  Google Scholar 

  14. Novara G, Galfano A, Secco S, D’Elia C, Cavalleri S, Ficarra V, et al. A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol. 2008;54(4):740–63.

    Article  CAS  PubMed  Google Scholar 

  15. Veenboer PW, Bosch JL. Long-term adherence to antimuscarinic therapy in everyday practice: a systematic review. J Urol. 2014;191(4):1003–8.

    Article  CAS  PubMed  Google Scholar 

  16. Sears CL, Lewis C, Noel K, Albright TS, Fischer JR. Overactive bladder medication adherence when medication is free to patients. J Urol. 2010;183(3):1077–81.

    Article  PubMed  Google Scholar 

  17. Kanai A, Zabbarova I, Oefelein M, Radziszewski P, Ikeda Y, Andersson KE. Mechanisms of action of botulinum neurotoxins, beta3-adrenergic receptor agonists, and PDE5 inhibitors in modulating detrusor function in overactive bladders: ICI-RS 2011. Neurourol Urodyn. 2012;31(3):300–8. Excellent description and illustration of the mechanisms of B3-agonists and botox on the lower urinary tract.

    Article  CAS  PubMed  Google Scholar 

  18. Maman K, Aballea S, Nazir J, Desroziers K, Neine ME, Siddiqui E, et al. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. Eur Urol. 2014;65(4):755–65. This meta-analysis of several randomized control trials found that B3-agonist had no difference in efficacy with fewer side effects than antimuscarinics.

    Article  CAS  PubMed  Google Scholar 

  19. Cui Y, Zong H, Yang C, Yan H, Zhang Y. The efficacy and safety of mirabegron in treating OAB: a systematic review and meta-analysis of phase III trials. Int Urol Nephrol. 2014;46(1):275–84.

    Article  CAS  PubMed  Google Scholar 

  20. Abrams P, Kelleher C, Staskin D, Rechberger T, Kay R, Martina R, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (symphony). Eur Urol. 2014. The first phase 2 trial supporting the use of combination therapy, B3-agonists and antimuscarinics, is safe and possibly more efficacious.

  21. Chancellor M, Levanovich P, Bharathi R, Vereecke A. Optimum management of overactive bladder: medication vs Botox vs InterStim vs Urgent PC. Urol Pract. 2014;1(1):7–12. The authors recommend a treatment algorithm for refractory overactive bladder based on the current and relevant literature.

    Article  Google Scholar 

  22. Balchandra P, Rogerson L. Women’s perspective: intra-detrusor botox versus sacral neuromodulation for overactive bladder symptoms after unsuccessful anticholinergic treatment. Int Urogynecol J. 2014;25(8):1059–64. Excellent prospective study into factors that influence treatment decisions for refractory overactive bladder.

    Article  PubMed  Google Scholar 

  23. Ginsberg D, Gousse A, Keppenne V, Sievert KD, Thompson C, Lam W, et al. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol. 2012;187(6):2131–9. A randomized, multicenter, placebo controlled study that reported on the safety and efficacy of 200 vs 300 units botox for neurogenic bladder. Significant improvements were found in overactive bladder symptoms and quality of life.

    Article  CAS  PubMed  Google Scholar 

  24. Nitti VW, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C, et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2013;189(6):2186–93. An excellent phase 3 trial that lead to FDA approval, which reported on the safety and efficacy of botox for refractory idiopathic overactive bladder.

    Article  CAS  PubMed  Google Scholar 

  25. Cruz F, Herschorn S, Aliotta P, Brin M, Thompson C, Lam W, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2011;60(4):742–50. Another of the randomized, multicenter, placebo controlled study that reported on the safety and efficacy of 200 vs 300 units botox for neurogenic bladder. Significant improvements were found in overactive bladder symptoms and quality of life.

    Article  CAS  PubMed  Google Scholar 

  26. Vainrib M, Simma-Chiang V, Boyd SD, Ginsberg DA. Potential risk factors and outcomes of artificial urinary sphincter placement after radical cystectomy and orthotopic neobladder urinary diversion. Neurourol Urodyn. 2013;32(7):1010–3.

    Article  PubMed  Google Scholar 

  27. Mohee A, Khan A, Harris N, Eardley I. Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB). BJU Int. 2013;111(1):106–13.

    Article  CAS  PubMed  Google Scholar 

  28. Dowson C, Watkins J, Khan MS, Dasgupta P, Sahai A. Repeated botulinum toxin type A injections for refractory overactive bladder: medium-term outcomes, safety profile, and discontinuation rates. Eur Urol. 2012;61(4):834–9.

    Article  CAS  PubMed  Google Scholar 

  29. White WM, Pickens RB, Doggweiler R, Klein FA. Short-term efficacy of botulinum toxin a for refractory overactive bladder in the elderly population. J Urol. 2008;180(6):2522–6.

    Article  CAS  PubMed  Google Scholar 

  30. Liao CH, Kuo HC. Increased risk of large post-void residual urine and decreased long-term success rate after intravesical onabotulinumtoxinA injection for refractory idiopathic detrusor overactivity. J Urol. 2013;189(5):1804–10.

    Article  CAS  PubMed  Google Scholar 

  31. Leng WW, Chancellor MB. How sacral nerve stimulation neuromodulation works. Urol Clin N Am. 2005;32(1):11–8.

    Article  Google Scholar 

  32. Kessler TM, La Framboise D, Trelle S, Fowler CJ, Kiss G, Pannek J, et al. Sacral neuromodulation for neurogenic lower urinary tract dysfunction: systematic review and meta-analysis. Eur Urol. 2010;58(6):865–74. This is a meta-analysis of sacral neuromodulation for neurogenic overactive bladder.

    Article  PubMed  Google Scholar 

  33. Banakhar MA, Al-Shaiji T, Hassouna M. Sacral neuromodulation and refractory overactive bladder: an emerging tool for an old problem. Ther Adv Urol. 2012;4(4):179–85.

    Article  PubMed Central  PubMed  Google Scholar 

  34. van Kerrebroeck PE, van Voskuilen AC, Heesakkers JP, Lycklama a Nijholt AA, Siegel S, Jonas U, et al. Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. J Urol. 2007;178(5):2029–34.

    Article  PubMed  Google Scholar 

  35. Siegel S, Noblett K, Mangel J, Griebling TL, Sutherland SE, Bird ET, et al. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder. Neurourol Urodyn. 2014. This study showed the benefit sacral neuromodulation over medications for overactive bladder. This is unlike the ABC and OrBIT study for botox and PTNS which were equivalent to medication.

  36. Jadav AM, Wadhawan H, Jones GL, Wheldon LW, Radley SC, Brown SR. Does sacral nerve stimulation improve global pelvic function in women? Colorectal Dis Off J Assoc Coloproctol Great Brit Ireland. 2013;15(7):848–57.

    Article  CAS  Google Scholar 

  37. Peters KM, Carrico DJ, Perez-Marrero RA, Khan AU, Wooldridge LS, Davis GL, et al. Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol. 2010;183(4):1438–43. Excellent percutaneous tibial nerve stimulation vs validated sham demonstrating improved overactive bladder outcomes and quality of life. This pivotal study lead to FDA approval of percutaneous tibial nerve stimulation.

    Article  PubMed  Google Scholar 

  38. Finazzi-Agro E, Petta F, Sciobica F, Pasqualetti P, Musco S, Bove P. Percutaneous tibial nerve stimulation effects on detrusor overactivity incontinence are not due to a placebo effect: a randomized, double-blind, placebo controlled trial. J Urol. 2010;184(5):2001–6.

    Article  PubMed  Google Scholar 

  39. Zecca CDG, Robshaw P, Singh A, Elneil S, Gobbi C. Maintenance percutaneous posterior nerve stimulation for refractory lower urinary tract symptoms in patients with multiple sclerosis: an open label, multicenter, prospective study. J Urol. 2014;191(3):697–702.

    Article  CAS  PubMed  Google Scholar 

  40. Staskin DR, Peters KM, MacDiarmid S, Shore N, de Groat WC. Percutaneous tibial nerve stimulation: a clinically and cost effective addition to the overactive bladder algorithm of care. Curr Urol Rep. 2012;13(5):327–34.

    Article  PubMed Central  PubMed  Google Scholar 

  41. Burton C, Sajja A, Latthe PM. Effectiveness of percutaneous posterior tibial nerve stimulation for overactive bladder: a systematic review and meta-analysis. Neurourol Urodyn. 2012;31(8):1206–16. This is a meta-analysis of percutaneous tibial nerve for neurogenic overactive bladder.

    Article  CAS  PubMed  Google Scholar 

  42. Gilbert SM, Hensle TW. Metabolic consequences and long-term complications of enterocystoplasty in children: a review. J Urol. 2005;173(4):1080–6.

    Article  PubMed  Google Scholar 

  43. Resnick MJ, Koyama T, Fan KH, Albertsen PC, Goodman M, Hamilton AS, et al. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med. 2013;368(5):436–45.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  44. D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969–74.

    Article  PubMed  Google Scholar 

  45. Afraa TA, Campeau L, Mahfouz W, Corcos J. Urodynamic parameters evolution after artificial urinary sphincter implantation for post-radical prostatectomy incontinence with concomitant bladder dysfunction. Can J Urol. 2011;18(3):5695–8.

    PubMed  Google Scholar 

  46. Giannantoni A, Mearini E, Di Stasi SM, Mearini L, Bini V, Pizzirusso G, et al. Assessment of bladder and urethral sphincter function before and after radical retropubic prostatectomy. J Urol. 2004;171(4):1563–6.

    Article  PubMed  Google Scholar 

  47. Jura YH, Comiter CV. Urodynamics for postprostatectomy incontinence: when are they helpful and how do we use them? Urol Clin N Am. 2014;41(3):419–27. viii. A clear and concise review of when UDS testing is appropriate and what etiologies can contribute to LUTD after prostatectomy.

  48. DE Chung DB, Kurta J, Maschino A, Cronin A, Sandhu J. Detrusor underactivity is prevalent after radical prostatectomy: a urodynamic study including risk factors. Can Urol Assoc J. 2013;1(7):E33–7.

    Google Scholar 

  49. Liss MA, Morales B, Skarecky D, Ahlering TE. Phase 1 clinical trial of vesicare (solifenacin) in the treatment of urinary incontinence after radical prostatectomy. J Endourol 2014;28(10):1241–5.

  50. Siegel AL. Pelvic floor muscle training in males: practical applications. Urology. 2014;84(1):1–7.

    Article  PubMed  Google Scholar 

  51. Thiel DD, Young PR, Broderick GA, Heckman MG, Wehle MJ, Igel TC, et al. Do clinical or urodynamic parameters predict artificial urinary sphincter outcome in post-radical prostatectomy incontinence? Urology. 2007;69(2):315–9.

    Article  PubMed  Google Scholar 

  52. Trigo Rocha F, Gomes CM, Mitre AI, Arap S, Srougi M. A prospective study evaluating the efficacy of the artificial sphincter AMS 800 for the treatment of postradical prostatectomy urinary incontinence and the correlation between preoperative urodynamic and surgical outcomes. Urology. 2008;71(1):85–9.

    Article  PubMed  Google Scholar 

  53. Winters JC, Appell RA, Rackley RR. Urodynamic findings in postprostatectomy incontinence. Neurourol Urodyn. 1998;17(5):493–8.

    Article  CAS  PubMed  Google Scholar 

  54. Gelblum DY, Potters L, Ashley R, Waldbaum R, Wang XH, Leibel S. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. Int J Radiat Oncol Biol Phys. 1999;45(1):59–67.

    Article  CAS  PubMed  Google Scholar 

  55. Jacobs SA, Lane FL, Osann KE, Noblett KL. Randomized prospective crossover study of interstim lead wire placement with curved versus straight stylet. Neurourol Urodyn. 2014;33(5):488–92.

    Article  PubMed  Google Scholar 

  56. Jacobs BL, Smith RP, Beriwal S, Benoit RM. Changes in lower urinary tract symptoms after prostate brachytherapy. J Contemp Brachytherapy. 2011;3(3):115–20.

    Article  PubMed Central  PubMed  Google Scholar 

  57. Ash D, Bottomley D, Al-Qaisieh B, Carey B, Gould K, Henry A. A prospective analysis of long-term quality of life after permanent I-125 brachytherapy for localised prostate cancer. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2007;84(2):135–9.

    Article  Google Scholar 

  58. Merrick GS, Butler WM, Wallner KE, Lief JH, Galbreath RW. Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy. Urology. 2002;60(4):650–5.

    Article  PubMed  Google Scholar 

  59. Shimizu N, Minami T, Sugimoto K, Saito Y, Yamamoto Y, Hayashi T, et al. Efficacy of silodosin in patients undergoing brachytherapy: a randomized trial involving a pressure flow study. World J Urol. 2014;32:1423–32.

  60. Boettcher M, Haselhuhn A, Jakse G, Brehmer B, Kirschner-Hermanns R. Overactive bladder syndrome: an underestimated long-term problem after treatment of patients with localized prostate cancer? BJU Int. 2012;109(12):1824–30.

    Article  PubMed  Google Scholar 

  61. Bittner N, Merrick GS, Brammer S, Niehaus A, Wallner KE, Butler WM, et al. Role of trospium chloride in brachytherapy-related detrusor overactivity. Urology. 2008;71(3):460–4.

    Article  PubMed  Google Scholar 

  62. Chou RH, Wilder RB, Ji M, Ryu JK, Leigh BR, Earle JD, et al. Acute toxicity of three-dimensional conformal radiotherapy in prostate cancer patients eligible for implant monotherapy. Int J Radiat Oncol Biol Phys. 2000;47(1):115–9.

    Article  CAS  PubMed  Google Scholar 

  63. Cahlon O, Zelefsky MJ, Shippy A, Chan H, Fuks Z, Yamada Y, et al. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys. 2008;71(2):330–7.

    Article  CAS  PubMed  Google Scholar 

  64. Yalla SV, Andriole GL. Vesicourethral dysfunction following pelvic visceral ablative surgery. J Urol. 1984;132(3):503–9.

    CAS  PubMed  Google Scholar 

  65. Plotti F, Angioli R, Zullo MA, Sansone M, Altavilla T, Antonelli E, et al. Update on urodynamic bladder dysfunctions after radical hysterectomy for cervical cancer. Crit Rev Oncol Hematol. 2011;80(2):323–9.

    Article  PubMed  Google Scholar 

  66. Nesbakken A, Nygaard K, Bull-Njaa T, Carlsen E, Eri LM. Bladder and sexual dysfunction after mesorectal excision for rectal cancer. Br J Surg. 2000;87(2):206–10.

    Article  CAS  PubMed  Google Scholar 

  67. Havenga K, Enker WE, McDermott K, Cohen AM, Minsky BD, Guillem J. Male and female sexual and urinary function after total mesorectal excision with autonomic nerve preservation for carcinoma of the rectum. J Am Coll Surg. 1996;182(6):495–502.

    CAS  PubMed  Google Scholar 

  68. Lee DK, Jo MK, Song K, Park JW, Moon SM. Voiding and sexual function after autonomic-nerve-preserving surgery for rectal cancer in disease-free male patients. Korean J Urol. 2010;51(12):858–62.

    Article  PubMed Central  PubMed  Google Scholar 

  69. Katepratoom C, Manchana T, Amornwichet N. Lower urinary tract dysfunction and quality of life in cervical cancer survivors after concurrent chemoradiation versus radical hysterectomy. Int Urogynecol J. 2014;25(1):91–6.

    Article  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Forrest Jellison declares no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Division of Urology, Pelvic Medicine and Reconstructive Surgery, Department of Surgery, Uniformed Services University of the Health Sciences, 3551 Roger Brooke Dr., Fort Sam Houston, TX, 78234, USA

    Forrest C. Jellison

Authors
  1. Forrest C. Jellison
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Forrest C. Jellison.

Additional information

This article is part of the Topical Collection on Overactive Bladder

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jellison, F.C. Evaluation and Treatment of Overactive Bladder after History of Cancer Treatment. Curr Bladder Dysfunct Rep 10, 31–38 (2015). https://doi.org/10.1007/s11884-014-0279-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11884-014-0279-y

Keywords

Search

Navigation